Abstract: A process for expressing extracellular .beta.-glucosidase in a filamentous fungus by expressing a fungal DNA sequence encoding enhanced, deleted or altered .beta.-glucosidase in a recombinant host microorganism is disclosed. Recombinant fungal cellulase compositions containing enhanced, deleted or altered expression of .beta.-glucosidase is also disclosed.

Abstract: A method of synthesis of new and useful single-stranded DNAs which have a stem-loop configuration (ss-slDNA). The method is an in vivo or an in vitro synthesis. Replicating vehicles which produce these ss-slDNAs. The ss-slDNAs are described. Uses for these slDNAs are disclosed. They can be used for introducing random mutations, they lend themselves for replication by a variant of the PCR method. They can also be used for regulating gene function. Other uses are disclosed.

Abstract: This invention discloses novel detection methods for determining the presence of a target compound in a substance using nucleic acid ligands as detection molecules. Specifically, the substance is bound to a solid support matrix, such as those used in blot procedures, and detection of the target molecule is accomplished using the affinity and specificity of nucleic acid ligands to the target molecule. The method utilized herein for identifying and preparing said nucleic acid ligands is called SELEX. The method of the present invention is additionally useful to isolate the target compounds from the various substances.

Abstract: Method for screening for a non-hormone agent potentially useful to treat a hormone disorder. The method involves contacting a potential agent with a system containing a cellular component and a translation factor. The component and factor interact with one another in an intact normal cell in a manner responsive to the hormone to cause a modulation of translation in the cell. The method involves determining whether the agent causes a modulation of translation by the component and the factor analogous to that which occurs in intact cells in response to the hormone.

Abstract: An endonuclease and its method of use for the detection of mutations in targeted polynucleotide sequences are provided, which facilitate the localization and identification of mutations, mismatches and genetic polymorphisms.

Abstract: A novel cyclin, termed prad1, is disclosed, along with the nucleic acid sequence that encodes human prad1. Antibodies that bind specifically to prad1 and cell lines and transgenic animals containing DNA that encodes prad1 are also disclosed. In addition, methods of using the antibodies or fragments of the nucleic acid sequence, for example, to diagnose a neoplastic condition by detecting expression of prad1 or to modulate cellular proliferation, are disclosed.

Abstract: A method of genotyping of HCV isolates using probes targeting sequences from the 5- untranslated region of HCV.

Abstract: Polynucleotide and polypeptide sequences encoding a novel tumor suppressor, HIC-1, are provided. Also included is a method for detecting a cell proliferative disorder associated with HIC-1. HIC-1 is a marker which can be used diagnostically, prognostically and therapeutically over the course of such disorders.

Abstract: The present invention features a method for introducing hypermutations into a target DNA or RNA sequence of interest, characterized in that said method comprises the steps of:(a) transcribing a RNA into DNA in a reaction mixture comprising a reverse transcriptase, varying biased concentrations of deoxynucleoside triphosphates to produce hypermutations and an oligonucleotide primer that is partially complementary to the 3' end of said RNA; and(b) recovering said DNA sequences.

Abstract: In one aspect, the present invention provides an in situ process of simultaneously detecting a specific predetermined nucleic acid sequence and a specific predetermined cellular antigen in the same cell. In accordance with that process, the antigen is labeled with a biotin- or DNP-tagged antibody that specifically immunoreacts with the antigen, the specific nucleic acid sequences in the cell are amplified, the amplified nucleic acid sequences are labeled with a fluorescently-tagged nucleic acid probe that specifically hybridizes to the amplified nucleic acid sequences, and the labeled nucleic acid sequences and labeled cellular antigen are detected.

Abstract: The field of this invention is the detection and isolation of specific amplified DNA sequences by flow cytometry. More particularly, this invention relates to the detection of these specific amplified DNA sequences in cells so as to allow quantitation of viral burden of patients infected with a virus. The method is particularly adapted to detection of HIV-1 proviral DNA sequences and the assessment of activity of the virus in a cell.

Abstract: The present invention relates to the Grb3-3 protein, nucleotide sequence encoding this protein, and variants thereof, such as antisense sequences. The invention further relates to vectors comprising these sequences and to methods for inducing cell death.

Abstract: Novel methods and kits for detecting mismatches in nucleic acids using one or more resolvase enzymes. These methods can be used in medical procedures or research, veterinary procedures or research, agricultural applications, forensics, and paternity testing. For example, in forensics and paternity testing, methods of the invention can replace or complement RFLP mapping.

Abstract: A method of identifying the presence of activated T-cells in a sample containing a plurality of different cell types is disclosed. The method includes the detection of polynucleotide sequences selectively expressed in activated T-cells.

Abstract: An assay for detecting mutations in genes by a two-step multiplex polymerase chain reaction amplification followed by preferably two-dimensional electrophoretic separation of the fragments on the basis of both size and base pair sequence.

Abstract: The present invention relates to somatic mutations in the Multiple Tumor Suppressor (MTS) gene in human cancers and their use in the diagnosis and prognosis of human cancer. The invention further relates to germ line mutations in the MTS gene and their use in the diagnosis of predisposition to melanoma, leukemia, astrocytoma, glioblastoma, lymphoma, glioma, Hodgkin's lymphoma, CLL, and cancers of the pancreas, breast, thyroid, ovary, uterus, testis, kidney, stomach and rectum. The invention also relates to the therapy of human cancers which have a mutation in the MTS gene, including gene therapy, protein replacement therapy and protein mimetics. Finally, the invention relates to the screening of drugs for cancer therapy.

Abstract: Rapid screening methods are described for determining human patients at risk of developing cardiovascular disease. The screening involves, for example, comparing an angiotensin-converting enzyme genomic DNA of a patient with a sequence region of angiotensin-converting enzyme gene from a person with no mutations in the region. The invention features methods of analyzing the predisposition of patients to cardiovascular disease which involves detecting small deletions, insertions, and point mutations in the angiotensin-converting enzyme gene. Small deletions, insertions, or point mutations can be detected by detecting mismatches between an angiotensin-converting enzyme genomic DNA sequence or angiotensin-converting enzyme genomic DNA-polymerase chain reaction products from a patient and a probe specific for a sequence region of angiotensin-converting enzyme gene from a person with no mutations in the region.

Abstract: The invention relates to a method of identifying the individual autosomal and sex chromosomes of a human karyotype through the use of a set of combinatorially labeled oligonucleotide probes each member thereof: (i) having a predetermined label distinguishable from the label of any other member of said set, and (ii) being capable of specifically hybridizing with one predetermined autosomal or sex chromosome of a human karyotype.

Abstract: The invention provides improved methods of introducing site-directed mutations into circular DNA molecules of interest by means of mutagenic primer pairs. The mutagenic primer pairs are also selected so as to be either completely complementary or partially complementary to each other, wherein the mutation site (or sites) is located within the region of complementarity. A mutagenic primer pair is annealed to opposite strands of a circular DNA molecule containing the DNA sequence to be mutagenized. After annealing, first and second mutagenized DNA strands, each incorporating a member of the mutagenic oligonucleotide primer pair is synthesized by a linear cyclic amplification reaction. After the linear cyclic amplification mediated synthesis step is completed, the reaction mixture is treated with a selection enzyme that digests the parental template strands. After the digesting step, a double-stranded circular DNA intermediate is formed.

Abstract: The invention relates to a method for determining a metal present in a sample, in which methoda) a recombinant DNA plasmid the copy number of which is under the control of a promoter regulatable by the metal is transferred into the cell, or a recombinant DNA plasmid the copy number of which can be varied between 1 and 2000/cell is transferred into the cell, and the plasmid contains as a marker protein a DNA sequence coding for a virus, procaryotic cell or eucaryotic cell protein or for a portion thereof essential for its biological activity, the expression of the DNA sequence being under the control of a promoter regulatable by the metal and being controlled by negative and/or positive feedback;b) the cell containing the recombinant DNA plasmid is contacted with a metal-containing sample;c) the metal is allowed to affect for a suitable time the cell which contains the recombinant DNA plasmid, whereafter the amount of recombinant DNA plasmid or the amount of protein encoded by it is determined by either physic